**Kurt Heiar**

**Dr. Kristi Thiel FOR IMMEDIATE RELEASE**

**Immortagen, Inc. 09/19/2016**

[**www.immortagen.com**](http://www.immortagen.com)

**info@immortagen.com**

**Immortagen Announces Completion of Series A Financing**

**Coralville, IA:** September 19, 2016. Immortagen, Inc., a University of Iowa spin-off venture, announced it has completed its Series A equity financing. Led by John Pappajohn of Des Moines, Iowa, Immortagen has already hired its initial scientists and begun increasing its industry presence, while pushing forward with several product platforms.

Launched in 2014 by University of Iowa researchers Donghai Dai, MD, PhD, MS, Kristina Thiel, PhD, Baoli Yang, MD, PhD and Kimberly Leslie, MD, Immortagen is a cutting edge women’s cancer company that is developing genetic analysis tools for personalized medicine. These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.

Of the Company’s recent financing, Immortagen President & CEO Kurt F. Heiar said, “Our initial financing will allow us to continue to develop our prototype artificial

intelligence-based algorithms, which we believe have the potential to dramatically drive forward drug matching for the development of new oncology drugs and diagnostics. While we are initially focused on women’s cancers due to the world-class expertise of our four Founders, we ultimately believe our portfolio will be applicable to a broad range of solid tumors.”

Vice President Biden’s Cancer Moonshot Initiative placed personalized medicine in the national spotlight. The ultimate goal of personalized medicine is to custom-design cancer therapies for each individual patient based on his/her tumor’s unique genetic properties. Dr. Kristi Thiel, Co-Founder and Vice President of Business Development at Immortagen, commented, “Our product pipeline fills a key gap in the interpretation of tumor genetic data. This information may help industry and physicians alike to treat each patient with a drug that is most likely to be effective, and hence improve patient outcomes.”

**About Immortagen, Inc.:** Immortagen, Inc. was selected as the University of Iowa Start Up of the Year for 2016 and is based in Coralville, Iowa. Immortagen previously received funding from the Iowa Economic Development Authority and the University of Iowa GAP Commercialization Fund. For more information, please go to [www.immortagen.com](http://www.immortagen.com).

Contact Information:

Kurt Heiar – kurt@immortagen.com

Kristi Thiel, Ph.D. – kristi@immortagen.com